EscharEx Emerging Drug Insight

“EscharEx Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about EscharEx for chronic wounds in the seven major markets. A detailed picture of the EscharEx for chronic wounds in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the EscharEx for chronic wounds. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EscharEx market forecast analysis for chronic wounds in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic wounds.

Drug Summary

EscharEx, next-generation enzymatic therapy under the developmental pipeline of MediWound, is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds. EscharEx active pharmaceutical ingredient (API) is a concentrate of proteolytic enzymes enriched in bromelain. It is a mixture of proteolytic enzymes for managing the debridement of chronic and other hard-to-heal wounds. It is easy to use, nonsurgical topical application, which demonstrated safety and efficacy in the debriding of chronic wounds in several etiologies within a few daily applications.

In December 2021, the company announced positive initial data from seven of the 15 patients in an ongoing open-label, Phase II pharmacology study of EscharEx in the debridement of lower leg ulcers (VLUs and DFUs). In January 2022, the company announced positive topline results from the ongoing Phase II study to treat VLUs. These topline results suggest that the study met its primary endpoint, demonstrating that patients treated with EscharEx had a statistically significant higher incidence of complete debridement than the gel vehicle, with a p-value of 0.004.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the EscharEx description, mechanism of action, dosage and administration, research and development activities in chronic wounds.
• Elaborated details on EscharEx regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EscharEx research and development activities in chronic wounds across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EscharEx.
• The report contains forecasted sales of for chronic wounds till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic wounds.
• The report also features the SWOT analysis with analyst views for EscharEx in chronic wounds.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EscharEx Analytical Perspective by DelveInsight

• In-depth EscharEx Market Assessment

This report provides a detailed market assessment of EscharEx for chronic wounds in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• EscharEx Clinical Assessment

The report provides the clinical trials information of EscharEx for chronic wounds covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic wounds is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EscharEx dominance.
• Other emerging products for chronic wounds are expected to give tough market competition to EscharEx and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EscharEx in chronic wounds.
• Our in-depth analysis of the forecasted sales data of EscharEx from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EscharEx in chronic wounds.

Key Questions

• What is the product type, route of administration and mechanism of action of EscharEx?
• What is the clinical trial status of the study related to EscharEx in chronic wounds and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EscharEx development?
• What are the key designations that have been granted to EscharEx for chronic wounds?
• What is the forecasted market scenario of EscharEx for chronic wounds?
• What are the forecasted sales of EscharEx in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to EscharEx for chronic wounds?
• Which are the late-stage emerging therapies under development for the treatment of chronic wounds?